A lot of Big Pharma companies were on the sidelines because they were unclear how cannabinoid therapeutics would be regulated by the FDA,” explains Alex Wasyl, CEO of Nexien BioPharma.
So, why should pharma care about digital therapeutics? This was just one of the questions posed to a panel of digital therapeutics experts during the 2018 CNS Summit.
While some might think Orchard’s whirlwind rise to be a bit of luck and good timing, the reality is it involved an extremely well-executed plan — and maybe a small dose of good fortune.
An exclusive interview with Rachel King, a business person dedicated to a science-driven sector, who is CEO of GlycoMimetics, an oncology-focused biotechnology company.
Bari Kowal, VP and head of global clinical operations at Regeneron, says sponsors and CROs must partner to make clinical trial execution more efficient and cost-effective.
An inside look at how CEO Yuval Cohen communicates and interacts with employees at Corbus Pharmaceuticals, and how all of that affects the company’s culture.
Medicines360 is using all its developed-world revenue to extend access to essential medicines to all women, regardless of the economic and healthcare circumstances in their part of the world.
Sometimes it’s difficult to separate the identity of a company from that of its CEO. For example, when we think of Amazon and Microsoft we naturally think of Jeff Bezos and Bill Gates. In the biopharmaceutical industry, it is hard to ponder Alkermes without thinking of Richard Pops.
How we can fix biopharma’s broken and battered image was the topic of a panel of seven biopharma executives convened this year by Life Science Leader at the JPM Conference in San Francisco.
Garo Armen, CEO of Agenus and a long-time pharma industry veteran, has shown the instincts for simple money-making on one hand and the humanitarian side of biopharma on the other.
Deborah Waterhouse discusses her journey toward becoming CEO of ViiV Healthcare, an HIV joint venture between GSK, Pfizer and Shionogi, and her focus as a leader around innovation, building the “trust agenda” and company performance.
What makes a successful merger? Here we look at the 2018 merger between genome-therapy-focused company Sangamo Therapeutics and TxCell, which focuses on regulatory T-cell (Treg) development for immunological diseases.
Tim Scott, founder and CEO at both a CDMO and start-up biotech, maps out financial understanding for leaders of both approaches.
A retired pharma executive decides to tackle the daunting task of revamping the U.S. healthcare system.
Bassil Dahiyat, Ph.D., president and CEO of Xencor, shares his perspective on why full-time equivalent (FTE) partnering deals are money losers.
Bassil Dahiyat, Ph.D., president and CEO of Xencor, a publicly traded biotech he founded right out of graduate school, shares three formative experiences gained as a first-time entrepreneur.
The career path of Orchard Therapeutics’ CEO Mark Rothera provides insight into how the executive came to be a champion of rare disease drug development.
While the annual BIO International Convention and Conference has much in common with the annual J.P. Morgan Healthcare Conference, first time attendee of BIO, Matt Pillar, quickly picks up on key points of differentiation at BIO 2019 this year in Philadelphia, PA, June 3 - 6.
Rob Wright provides insight into the categories and shared attributes of superbosses, as derived from 10 years of research and more than 200 interviews by Sydney Finkelstein, #23 on the Thinker50 2017 rankings.
